放疗联合艾迪注射液治疗鼻咽癌疗效与预后因子的临床研究

Radiotherapy combined with AiDi for asopharynx cancer and the prognostic factor

目的探讨艾迪等中药制剂在鼻咽癌放疗中的作用。方法随机将鼻咽癌患者分为两组，实验组在放疗同期同时给予静脉滴注艾迪注射液，对照组仅予以放疗及化疗。放疗中期及放疗结束后分别检查实验组及对照组的鼻咽部MR及EB病毒指标、血常规、KPS评分、体重等，并采用SPSS16．0软件进行统计学分析。结果实验组及对照组在降低EA—IgA（治疗后1周及2周P值分别为0．036、0．034）、VCA—IgA（治疗后1周及2周P值分别为0．01、0．01）及DNA拷贝（治疗后1周及2周P值分别为0．01、0．005）上存在统计学差异，CR率等无明显统计学差异。结论艾迪注射液能有效降低EBV病毒DNA拷贝及滴度，但并不能提高肿瘤缓解率。

Objective To investigate the efficacy of AiDi for nasopharynx cancer. Methods Patients with nasopharynx cancer were randomly assigned to experiment group and control group. And the experiment group were treated with AiDi and rediochemotherapy while the control group took only radiochemotheapy. After the whole therapy, the MRI of nasopharynx, EBV-DNA, blood test, weight were tested. And the data were analyzed with SPSS 16.0 software.Results The EBV-DNA in the experiment group were obviously reduced, but there was no statistical difference in CR. Conclusions AiDi could reduce the EBV-DNA and EBV Virus titer, but it can＇ t improve the remission rate.